Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

802.83 -16.55 (-2.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Eli Lilly (LLY) Stock Trades Down, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.1% in the afternoon session after the company halted a mid-stage clinical trial for its experimental drug, bimagrumab, which was... 
Via StockStory
Topics Artificial Intelligence
Eli Lilly Stock Is Trading Down Thursday: What's Behind The Move?
Eli Lilly and Company (NYSE: LLY) shares are trading lower after the company ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it... 
Via Benzinga
AI Takes Center Stage in Biodefense: DARPA's NODES Program Promises to Revolutionize Pandemic and Biowarfare Protection
In a groundbreaking leap for global health security, the Defense Advanced Research Projects Agency (DARPA) officially launched its Network of Optimal Dynamic Energy Signatures (NODES) program in July... 
Via MarketMinute
Topics Artificial Intelligence
Eli Lilly Terminates Study Of Bimagrumab In Obesity
Via Stocktwits
Eli Lilly Announces Plan To Construct New $6.5B Facility In Texas
Via Stocktwits
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Via Stocktwits
Topics Intellectual Property
Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch
On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began. 
Via Benzinga
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
The latest data from the company's oral weight loss drug is bullish for the stock. 
Via The Motley Fool
Topics Economy
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering.
Investors once speculated that Pfizer might consider acquiring Viking. 
Via The Motley Fool
3 Small-Cap Stocks We Keep Off Our Radar
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Healthcare Sector Grapples with 5% Slump in 2025: A Deep Dive into Market Underperformance
The healthcare sector finds itself in turbulent waters in 2025, registering a concerning 5% slump and significantly lagging the overall S&P 500 index. This downturn marks a continuation of a multi-year... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
Does Eli Lilly's New $5 Billion Drug Manufacturing Facility Make It a Long-Term Buy?
Once up and running, it and other projects should make the company's supply chain stronger. 
Via The Motley Fool
Topics Artificial Intelligence Economy
United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines. 
Via Benzinga
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
 
Via Benzinga
Topics ETFs
STRATA Skin Sciences Soars as Landmark Study Reveals Superior Vitiligo Treatment Efficacy
STRATA Skin Sciences Inc. (NASDAQ: SSKN) witnessed a dramatic surge in its stock price today, climbing 51.18% following the publication of a groundbreaking peer-reviewed study. The research highlights... 
Via MarketMinute
Topics Intellectual Property
The Magnificent 7 Boom Just Triggered A Dot-Com Era Warning
The Magnificent Seven tech giants are now worth $21 trillion—8x more than top health care stocks, echoing dot-com bubble extremes. 
Via Benzinga
What's Pfizer Getting in Its $7.3 Billion Metsera Buyout?
Pfizer's plan to enter the booming obesity market took an expensive new turn. 
Via The Motley Fool
Nvidia’s $100B Bet in OpenAI Pushes Wall Street to Fresh Records
Tech did the heavy lifting as Nvidia and Apple dragged indexes over the finish line; gold hit yet another all-time high while oil sagged. The Fed chorus grew louder and more discordant. 
Via Chartmill
Topics Economy
Unpacking the Latest Options Trading Trends in Eli Lilly
 
Via Benzinga
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
As the global economy marches towards the final quarter of 2025, investors find themselves at a pivotal juncture, balancing cautious optimism with an awareness of lingering uncertainties. Moderating... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
The pharmaceutical industry is currently witnessing a transformative battle for dominance in the burgeoning weight-loss drug market, with Eli Lilly (NYSE: LLY) firmly at the forefront. What was once a... 
Via MarketMinute
Topics Economy Intellectual Property
Roche Targets Top Spot In Weight Loss Drug Market
Roche advances weight loss drug CT-388 to Phase III, boosts pipeline with major acquisitions. 
Via Benzinga
Healthcare Sector Outlook: Navigating Regulatory Headwinds and Breakthrough Innovations
The healthcare sector is currently experiencing a period of profound transformation, marked by a fascinating dichotomy: groundbreaking medical innovations are driving unprecedented growth for some,... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
The pharmaceutical landscape is currently a tale of two giants employing vastly different, yet highly successful, growth strategies. Eli Lilly and Company (NYSE: LLY) has placed an extraordinary bet on... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Eli Lilly and Company (NYSE: LLY) has reported a stellar second quarter for 2025, significantly exceeding market expectations and cementing its position as a dominant force in the burgeoning obesity... 
Via MarketMinute
Topics Economy
NVIDIA's AI Engine Roars On: Data Center Dominance Fuels Stellar Q2, But Market Seeks More
NVIDIA (NASDAQ: NVDA) continues to be the undisputed titan in the artificial intelligence arena, recently unveiling a dazzling Q2 fiscal year 2026 earnings report that underscored its foundational role... 
Via MarketMinute
Topics Artificial Intelligence Earnings Economy
Is Eli Lilly Stock a Buy After Gaining 10% in 1 Month?
The drugmaker continues to lead the increasingly competitive market for weight management drugs. 
Via The Motley Fool
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market
Pfizer Inc. (NYSE: PFE) stock climbed 1.87% in Monday pre-market amid reports that the company on the verge of acquiring Metsera Inc. (NASDAQ: MTSR), a developer of anti-obesity drugs. 
Via Benzinga
1 ETF to Buy Before the End of 2025
Why buy one growth stock when you can buy more than 300? 
Via The Motley Fool
Topics ETFs
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.